Adults who received the updated mRNA-1273 COVID-19 vaccine experienced a lower risk for hospitalization compared with NVX-CoV2705 recipients.

Intravenous lidocaine infusions for chronic pain are associated with a low incidence of serious adverse events, according to recent study results.

Both non-HDL-C and apolipoprotein B levels independently predict ASCVD risk in patients not receiving statins.

Engaging in moderate to vigorous physical activity concentrated over 1 to 2 days per week may confer survival benefits among adults with OA.

Right ventricular dysfunction (RVD) is prevalent in 41.7 percent of patients with heart failure with preserved ejection fraction (HFpEF).

The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).

Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

Cancer doctors across the US are running short of essential generic chemotherapy drugs, sparking fear of widespread rationing.

A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Patients with systemic lupus erythematosus (SLE) without lupus nephritis (LN) have increased risk of chronic kidney disease and mortality.